Evidence, not endorsement
Protocol library
Regimens are reported in their study or label context. Confidence describes how directly the cited evidence maps to the compound and formulation, not expected benefit.
| Protocol | Type | Evidence | Confidence | Status |
|---|---|---|---|---|
| 5-Amino-1MQ A small-molecule NNMT inhibitor with cell and animal metabolic research. It is not a peptide and no validated human protocol has been established. | Single | Preclinical | Very Low | Sourced |
| ACE-031 An activin receptor fusion protein studied in early human trials. Development in Duchenne muscular dystrophy stopped after vascular safety concerns. | Single | Early Human | Low | Sourced |
| AHK-Cu A copper-binding tripeptide investigated mainly in laboratory and cosmetic hair or skin contexts. Evidence does not establish a systemic injectable protocol. | Single | Preclinical | Very Low | Sourced |
| AOD-9604 A modified growth-hormone fragment investigated for obesity. Human development did not establish an authorised obesity treatment or a routine-use protocol. | Single | Early Human | Low | Sourced |
| ARA-290 / Cibinetide An erythropoietin-derived tissue-protective peptide studied in small phase 2 neuropathy trials. Schedules are disease-specific and remain investigational. | Single | Phase 2 | Moderate | Sourced |
| BPC-157 An investigational gastric peptide fragment with extensive preclinical claims but extremely limited and uncontrolled human evidence across oral, local and intravenous routes. | Single | Mixed | Very Low | Sourced |
| BPC-157 / TB-500 blend A combined research product without controlled human evidence for the mixture. Component-level preclinical claims do not establish compatibility or a blend protocol. | Blend | Mixed | Very Low | Sourced |
| Bremelanotide A melanocortin receptor agonist with an authorised US auto-injector for a defined indication. Research-vial calculations are not equivalent to the regulated product. | Single | Regulatory Label | High | Sourced |
| Cagrilintide A long-acting amylin analogue under clinical investigation for weight management, with dose-ranging human evidence but no routine-use authorisation. | Single | Phase 2 | Moderate | Sourced |
| Cagrilintide and semaglutide An investigational fixed-ratio combination studied through phase 3 under sponsor-controlled protocols. The programme does not validate mixing separate consumer vials. | Blend | Phase 3 | Moderate | Sourced |
| Cartalax A short peptide bioregulator marketed for cartilage-related claims. Internationally indexed controlled human evidence is too sparse to establish a protocol. | Single | Preclinical | Very Low | Sourced |
| CJC-1295 no DAC A short-acting GHRH analogue name that does not map to the long-acting DAC-linked CJC-1295 used in the best-known human trials. | Single | Mixed | Very Low | Sourced |
| DSIP A small neuropeptide investigated in older and heterogeneous sleep experiments. The literature does not support a current standard administration protocol. | Single | Early Human | Low | Sourced |
| Eloralintide A once-weekly selective amylin receptor agonist in phase 3 development, with published phase 2 arms spanning fixed and escalated 1 mg to 9 mg targets. | Single | Phase 2 | Moderate | Sourced |
| Enclomiphene An oral selective oestrogen receptor modulator studied for secondary hypogonadism. It is not a peptide and remains unapproved in major markets. | Single | Phase 3 | Moderate | Sourced |
| GHK-Cu A copper-binding tripeptide investigated mainly in laboratory, wound and topical cosmetic contexts. Evidence does not establish an injectable human regimen. | Single | Mixed | Low | Sourced |
| GLOW blend A three-component GHK-Cu, BPC-157 and TB-500 research blend. No controlled human evidence establishes this combined formulation or schedule. | Blend | Mixed | Very Low | Sourced |
| Glutathione An endogenous antioxidant studied in several oral and intravenous settings. Evidence is highly route- and indication-specific and does not validate subcutaneous research vials. | Single | Mixed | Low | Sourced |
| Gonadorelin Synthetic GnRH with specialist diagnostic and pulsatile fertility evidence. Clinical schedules rely on pumps, endocrine monitoring and indication-specific adjustment. | Single | Mixed | Moderate | Sourced |
| IGF-1 LR3 A long-acting IGF-1 research analogue used mainly in laboratory models. Clinical evidence for approved recombinant human IGF-1 does not transfer to LR3. | Single | Preclinical | Very Low | Sourced |
| Ipamorelin A ghrelin-receptor agonist with early human pharmacology and an intravenous phase 2 postoperative study. Neither establishes a routine subcutaneous wellness protocol. | Single | Early Human | Low | Sourced |
| Kisspeptin A reproductive neuropeptide studied in specialist fertility research. Molecule length, bolus versus infusion and ovarian context materially change the protocol. | Single | Early Human | Moderate | Sourced |
| KLOW blend A four-component GHK-Cu, BPC-157, KPV and TB-500 research blend with no controlled human evidence for the combined formulation. | Blend | Mixed | Very Low | Sourced |
| KPV A short anti-inflammatory peptide with cell and animal evidence. A related oral analogue, K(D)PT, reached a small phase 2a colitis study but is not identical to injectable KPV. | Single | Mixed | Low | Sourced |
| LL-37 A human antimicrobial peptide studied clinically as a topical wound product. Controlled evidence does not validate systemic or subcutaneous injection. | Single | Phase 2 | Low | Sourced |
| Melanotan 1 An alpha-MSH analogue best anchored to afamelanotide evidence. The authorised medicine is a 16 mg controlled-release implant, not a reconstituted research vial. | Single | Regulatory Label | Moderate | Sourced |
| Melanotan 2 An unapproved cyclic melanocortin analogue with very small early human studies. The published schedules are phase 1 experiments, not a validated tanning protocol. | Single | Early Human | Low | Sourced |
| MK-677 / Ibutamoren An oral, non-peptide ghrelin receptor agonist studied in several controlled trials. It is investigational and has no injectable formulation. | Single | Phase 2 | Moderate | Sourced |
| MOTS-C A mitochondrial-derived peptide supported mainly by cell and animal experiments. Human research largely measures endogenous MOTS-C rather than administering it. | Single | Preclinical | Very Low | Sourced |
| NAD+ A cellular coenzyme used in heterogeneous infusion and metabolic research. Human evidence does not establish a standard subcutaneous research-vial protocol. | Single | Mixed | Low | Sourced |
| Ovagen A peptide bioregulator marketed for ovarian and endocrine claims. Robust indexed human evidence is insufficient to establish a reproducible protocol. | Single | Preclinical | Very Low | Sourced |
| Oxytocin An authorised peptide hormone for specific obstetric indications. Labelled intravenous and intramuscular use requires professional monitoring and is not a wellness protocol. | Single | Regulatory Label | High | Sourced |
| Pinealon A short peptide bioregulator studied mainly in laboratory, ageing and limited regional clinical literature. Evidence quality and formulation mapping are weak. | Single | Mixed | Very Low | Sourced |
| Retatrutide A triple GIP, GLP-1 and glucagon receptor agonist in phase 3 development. Explore the TRIUMPH schedule and vial-aware calculation examples. | Single | Phase 3 | Moderate | Sourced |
| Retatrutide and cagrilintide A commonly discussed investigational pairing without a controlled human combination regimen. This page records the evidence gap and does not propose stack quantities. | Stack | Mixed | Very Low | Sourced |
| Selank A synthetic heptapeptide studied in small human and laboratory studies, with limited internationally accessible clinical evidence and no UK marketing authorisation. | Single | Early Human | Low | Sourced |
| Semaglutide A GLP-1 receptor agonist used in several authorised medicines. Formulation, indication and route are product-specific and must not be treated as interchangeable. | Single | Regulatory Label | High | Sourced |
| Semax A synthetic ACTH fragment analogue studied mainly in Russian-language and intranasal contexts. Evidence does not map cleanly to a reconstituted injectable vial. | Single | Mixed | Low | Sourced |
| Sermorelin A short growth-hormone-releasing hormone analogue with historical diagnostic and paediatric clinical use. Current research products may not match former medicines. | Single | Mixed | Low | Sourced |
| SLU-PP-332 A synthetic oestrogen-related receptor agonist often grouped with research peptides despite being a small molecule. Evidence remains preclinical. | Single | Preclinical | Very Low | Sourced |
| SNAP-8 A cosmetic signalling peptide developed for topical formulations. Laboratory and skin-product evidence does not support systemic injection. | Single | Preclinical | Very Low | Sourced |
| SS-31 / Elamipretide A mitochondria-targeting peptide approved in the US as Forzinity for a narrow Barth-syndrome population. The authorised formulation and indication do not validate generic SS-31 products. | Single | Regulatory Label | High | Sourced |
| TB-500 A synthetic fragment marketed by association with thymosin beta-4. Full-length thymosin beta-4 findings do not establish an injectable TB-500 protocol. | Single | Preclinical | Very Low | Sourced |
| Tesamorelin A growth hormone-releasing factor analogue with an authorised US medicine for a narrow indication. The label does not support general weight-loss or anti-ageing use. | Single | Regulatory Label | High | Sourced |
| Tesamorelin / Ipamorelin blend A growth-hormone-axis blend not represented by the authorised tesamorelin product or by the intravenous ipamorelin clinical programme. | Blend | Mixed | Very Low | Sourced |
| Testagen A peptide bioregulator promoted for testicular and reproductive claims. Adequate controlled human evidence is not available to define a protocol. | Single | Preclinical | Very Low | Sourced |
| Thymosin alpha-1 An immune-modulating peptide used in some jurisdictions and studied across highly varied infections, liver disease and immune conditions. | Single | Mixed | Moderate | Sourced |
| Tirzepatide A GIP and GLP-1 receptor agonist with authorised prescription products. Label regimens apply only to regulated medicines under clinical care. | Single | Regulatory Label | High | Sourced |
| VIP A vasoactive neuropeptide studied through intravenous, inhaled and other specialist routes. Rapid haemodynamic effects make route and monitoring central. | Single | Early Human | Low | Sourced |